Vaxart Inc. Stock
Vaxart Inc. Stock
With 0 Sell predictions and 1 Buy predictions the community sentiment towards the Vaxart Inc. stock is not clear.
Our community identified positive and negative aspects for Vaxart Inc. stock for the coming years. 2 users see the criterium "Worthwhile Investment for the next years" as a plus for the Vaxart Inc. stock. On the other hand our users think that "General Risks" could be a problem in the future.
Pros and Cons of Vaxart Inc. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
?
G***** c******* t* c**********
Cons
?
S********** s********
?
B****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Vaxart Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Vaxart Inc. | - | - | - | - | - | - | - |
| Larimar Therapeutics Inc. | -0.600% | -5.714% | 18.705% | 11.486% | -0.602% | -13.613% | -61.850% |
| Northwest Biotherapeutics Inc. | -9.460% | -13.548% | -8.844% | -31.633% | -34.951% | -70.485% | -87.358% |
| Achieve Life Sciences Inc. | 1.890% | 0.935% | -4.425% | 145.455% | 45.946% | 6.931% | -10.744% |
Comments
Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) had its "outperform" rating re-affirmed by analysts at William Blair.
Show more
Ratings data for AVIR provided by MarketBeat
News
Vaxart Investors Reject Say-on-Pay as CEO Rules Out Reverse Split for Now
Key Points
- Interested in Vaxart, Inc.? Here are five stocks we like better.
- Vaxart shareholders rejected the company’s say-on-pay proposal at its 2026 annual meeting, even as they re-elected
3 Stocks Under $5 With Strong Analyst Upside Potential
At a time when many investors are rotating out of speculative penny stocks, others continue to embrace the risk-reward dynamic. Stocks that trade for under $5 carry a certain amount of risk. Many